Cargando…

Nano drug delivery systems in upper gastrointestinal cancer therapy

Upper gastrointestinal (GI) carcinomas are characterized as one of the deadliest cancer types with the highest recurrence rates. Their treatment is challenging due to late diagnosis, early metastasis formation, resistance to systemic therapy and complicated surgeries performed in poorly accessible l...

Descripción completa

Detalles Bibliográficos
Autores principales: Salapa, Julia, Bushman, Allison, Lowe, Kevin, Irudayaraj, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728832/
https://www.ncbi.nlm.nih.gov/pubmed/33301056
http://dx.doi.org/10.1186/s40580-020-00247-2
_version_ 1783621356111265792
author Salapa, Julia
Bushman, Allison
Lowe, Kevin
Irudayaraj, Joseph
author_facet Salapa, Julia
Bushman, Allison
Lowe, Kevin
Irudayaraj, Joseph
author_sort Salapa, Julia
collection PubMed
description Upper gastrointestinal (GI) carcinomas are characterized as one of the deadliest cancer types with the highest recurrence rates. Their treatment is challenging due to late diagnosis, early metastasis formation, resistance to systemic therapy and complicated surgeries performed in poorly accessible locations. Current cancer medication face deficiencies such as high toxicity and systemic side-effects due to the non-specific distribution of the drug agent. Nanomedicine has the potential to offer sophisticated therapeutic possibilities through adjusted delivery systems. This review aims to provide an overview of novel approaches and perspectives on nanoparticle (NP) drug delivery systems for gastrointestinal carcinomas. Present regimen for the treatment of upper GI carcinomas are described prior to detailing various NP drug delivery formulations and their current and potential role in GI cancer theranostics with a specific emphasis on targeted nanodelivery systems. To date, only a handful of NP systems have met the standard of care requirements for GI carcinoma patients. However, an increasing number of studies provide evidence supporting NP-based diagnostic and therapeutic tools. Future development and strategic use of NP-based drug formulations will be a hallmark in the treatment of various cancers. This article seeks to highlight the exciting potential of novel NPs for targeted cancer therapy in GI carcinomas and thus provide motivation for further research in this field.
format Online
Article
Text
id pubmed-7728832
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-77288322020-12-17 Nano drug delivery systems in upper gastrointestinal cancer therapy Salapa, Julia Bushman, Allison Lowe, Kevin Irudayaraj, Joseph Nano Converg Review Upper gastrointestinal (GI) carcinomas are characterized as one of the deadliest cancer types with the highest recurrence rates. Their treatment is challenging due to late diagnosis, early metastasis formation, resistance to systemic therapy and complicated surgeries performed in poorly accessible locations. Current cancer medication face deficiencies such as high toxicity and systemic side-effects due to the non-specific distribution of the drug agent. Nanomedicine has the potential to offer sophisticated therapeutic possibilities through adjusted delivery systems. This review aims to provide an overview of novel approaches and perspectives on nanoparticle (NP) drug delivery systems for gastrointestinal carcinomas. Present regimen for the treatment of upper GI carcinomas are described prior to detailing various NP drug delivery formulations and their current and potential role in GI cancer theranostics with a specific emphasis on targeted nanodelivery systems. To date, only a handful of NP systems have met the standard of care requirements for GI carcinoma patients. However, an increasing number of studies provide evidence supporting NP-based diagnostic and therapeutic tools. Future development and strategic use of NP-based drug formulations will be a hallmark in the treatment of various cancers. This article seeks to highlight the exciting potential of novel NPs for targeted cancer therapy in GI carcinomas and thus provide motivation for further research in this field. Springer Singapore 2020-12-10 /pmc/articles/PMC7728832/ /pubmed/33301056 http://dx.doi.org/10.1186/s40580-020-00247-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Salapa, Julia
Bushman, Allison
Lowe, Kevin
Irudayaraj, Joseph
Nano drug delivery systems in upper gastrointestinal cancer therapy
title Nano drug delivery systems in upper gastrointestinal cancer therapy
title_full Nano drug delivery systems in upper gastrointestinal cancer therapy
title_fullStr Nano drug delivery systems in upper gastrointestinal cancer therapy
title_full_unstemmed Nano drug delivery systems in upper gastrointestinal cancer therapy
title_short Nano drug delivery systems in upper gastrointestinal cancer therapy
title_sort nano drug delivery systems in upper gastrointestinal cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728832/
https://www.ncbi.nlm.nih.gov/pubmed/33301056
http://dx.doi.org/10.1186/s40580-020-00247-2
work_keys_str_mv AT salapajulia nanodrugdeliverysystemsinuppergastrointestinalcancertherapy
AT bushmanallison nanodrugdeliverysystemsinuppergastrointestinalcancertherapy
AT lowekevin nanodrugdeliverysystemsinuppergastrointestinalcancertherapy
AT irudayarajjoseph nanodrugdeliverysystemsinuppergastrointestinalcancertherapy